02 Oct 2014 --- Lonza has been awarded a new patent for the ability of its ResistAid larch arabinogalactan, when administered with a vaccine, to enhance the adaptive immune response. The patent, No. US 8,784,844 B2, entails arabinogalactan’s ability to elicit a beneficial response from the adaptive immune system when administered with a vaccine in subjects prior, during and after the phase of exposure to a foreign antigen.
